Zentalis Pharmaceuticals, Inc.

ZNTL

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001725160

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $289.0M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data, degenerate in... not computable: distress, fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Mar 26, 2026 242 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026
Last close	$1.36 2026-11-20; market equity $134.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 26, 2026

We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, or PROC.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 70.1						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(3.3%)	(6.7%)	70.1	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 44.3					
Altman Z double-prime	(8.96)	0.31	61.4	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
one or more required annual facts are missing					
Current ratio	6.93x	2.68x	27.2	781	2025-12-31
Growth and financing, sleeve percentile 45.3					
Revenue growth, three-year compound	not computable	9.6%			
four annual observations are required; found 2					
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(18.8%)	3.2%	82.3	663	2025-12-31
Net share issuance, one year	(1.2%)	1.6%	8.3	626	2026-03-20

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 2.2 months
Thin data	5 of 13 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	84.7%	(1.7%)	88
Distance from 52-week high	(79.4%)	(33.0%)	10
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(93.7%)	0.6%	8
Book value to price	1.53	0.29	92
Sales to price	0.00	0.38	0
Composite equity issuance, five years	87.3%	13.5%	81
Relative strength against the sector, log excess return	0.44	(0.19)	88
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$24.0M
Operating cash flow, four quarters	-$133.8M
Months of runway	2.2
Days since last periodic filing	14 (10-Q received Nov 9, 2026)
Median daily dollar volume, 63 sessions	$2.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$137.1M	2025-12-31	2026-03-26	10-K	26-000014
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$125.2M	2025-12-31	2026-03-26	10-K	26-000014
3	assets	us-gaap:Assets	$289.0M	2025-12-31	2026-03-26	10-K	26-000014
4	assets	us-gaap:Assets	$430.3M	2024-12-31	2026-03-26	10-K	26-000014
5	current assets	us-gaap:AssetsCurrent	$253.2M	2025-12-31	2026-03-26	10-K	26-000014
6	current liabilities	us-gaap:LiabilitiesCurrent	$36.6M	2025-12-31	2026-03-26	10-K	26-000014
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.2B	2025-12-31	2026-03-26	10-K	26-000014
8	operating income	us-gaap:OperatingIncomeLoss	-$152.8M	2025-12-31	2026-03-26	10-K	26-000014
9	book equity	us-gaap:StockholdersEquity	$216.2M	2025-12-31	2026-03-26	10-K	26-000014
10	liabilities	us-gaap:Liabilities	$72.8M	2025-12-31	2026-03-26	10-K	26-000014
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2025-12-31	2026-03-26	10-K	26-000014
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$67.4M	2024-12-31	2026-03-26	10-K	26-000014
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2025-12-31	2026-03-26	10-K	26-000014
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$170.9M	2024-12-31	2026-03-26	10-K	26-000014
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$221,000	2024-12-31	2026-03-26	10-K	26-000014
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$207.8M	2023-12-31	2026-03-26	10-K	26-000014
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$583,000	2023-12-31	2026-03-26	10-K	26-000014
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$163.8M	2022-12-31	2025-03-26	10-K	25-000067
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.5M	2022-12-31	2025-03-26	10-K	25-000067
20	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$739,000	2025-12-31	2026-03-26	10-K	26-000014
21	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$136.6M	2025-12-31	2026-03-26	10-K	26-000014
22	income tax	us-gaap:IncomeTaxExpenseBenefit	$442,000	2025-12-31	2026-03-26	10-K	26-000014
23	current assets	us-gaap:AssetsCurrent	$386.1M	2024-12-31	2026-03-26	10-K	26-000014
24	current liabilities	us-gaap:LiabilitiesCurrent	$52.7M	2024-12-31	2026-03-26	10-K	26-000014
25	assets	us-gaap:Assets	$551.7M	2023-12-31	2025-03-26	10-K	25-000067
26	assets	us-gaap:Assets	$539.3M	2022-12-31	2024-02-27	10-K	24-000080
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	70,931,016	2026-03-20	2026-03-26	10-K	26-000014
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	71,811,508	2025-03-21	2025-03-26	10-K	25-000067

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.